PRELIMINARY REPORT OF THE USE ON ADULTS OF A RECOMBINANT YEAST-DERIVED HEPATITIS B VACCINE MANUFACTURED BY INSTITUTO BUTANTAN

• Published in: Revista do Instituto de Medicina Tropical de São Paulo
• Main Authors: Angela Aparecida COSTA, Marta INENAMI, Edmundo JUAREZ, Pedro Dorlhiac LLACEN, Isaias RAW
• Format: Article in Journal/Newspaper
• Language: English
• Published: Universidade de São Paulo (USP) 1997
• Subjects: Recombinant hepatitis B vaccine; Clinical trials; Adults; Arctic medicine. Tropical medicine; RC955-962; Infectious and parasitic diseases; RC109-216; Arctic
• Online Access: https://doi.org/10.1590/S0036-46651997000100008; https://doaj.org/article/8a0e29a3fea846caaedc141c761b9fec

Three 10 µg doses of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in a adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immunogenicity (anti-HBs titers between 17.5-29500 IU/l, seroconversion 95.3%) and reactogenicity (no incapacitating side effects) Três doses de 10 µg da vacina recombinante contra hepatite B, produzida pelo Instituto Butantan, através de tecnologia própria, foram administradas numa população de adultos (idade média 30 anos), seguindo o esquema de imunização 0, 1 e 6 meses após a primeira dose. A avaliação clínica da vacina foi considerada satisfatória em termos de imunogenicidade (títulos dos anticorpos anti-HBs entre 17,5-29500 UI/1, soroconversão 95,3%) e reatividade (sem efeitos colaterais e sintomas clínicos relevantes)